Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (Diabody-CH3) (BSDBC-117)

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (Diabody-CH3) is a fusion protein of two diabodies connected together by a CH3 region. In a diabody, the two scFvs with short linkers are from anti-CD37 and anti-CD64 antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to each of the CH3 chains, which results in 2+2 antigen-binding valency and extends the half-life of this BsAb. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD37 & CD64

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL)

Targets

Target 1

CD37

Gene ID

951

UniProt ID

P11049

Alternative Names

CD37; CD37 molecule; GP52-40; TSPAN26; leukocyte antigen CD37; tspan-26; tetraspanin-26; leukocyte surface antigen CD37; cell differentiation antigen 37

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (Diabody-CH3) (BSDBC-117). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (Diabody-CH3) (CAT#: BSDBC-117)

Specifications

Targets

Customer Reviews and Q&As